Selected research
Market Outlook & Growth Opportunities
Global Personalized Therapy Biosimulation Platform Market Outlook and Growth Opportunities 2026
Market perspective
The global Personalized Therapy Biosimulation Platform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Personalized Therapy Biosimulation Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Personalized Therapy Biosimulation Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Personalized Therapy Biosimulation Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Personalized Therapy Biosimulation Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Personalized Therapy Biosimulation Platform market include Schrodinger, In Silico Biosciences, Genedata, Physiomics, Insilico Biotechology, Chemical Computing Group ULC(CCG), Evidera, AnyLogic and Shanghai Lide, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Personalized Therapy Biosimulation Platform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Personalized Therapy Biosimulation Platform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Personalized Therapy Biosimulation Platform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Personalized Therapy Biosimulation Platform market.
Personalized Therapy Biosimulation Platform Segment by Company
Schrodinger
In Silico Biosciences
Genedata
Physiomics
Insilico Biotechology
Chemical Computing Group ULC(CCG)
Evidera
AnyLogic
Shanghai Lide
Cellworks Group
Certara
Simulation Plus
Personalized Therapy Biosimulation Platform Segment by Type
Pharmacokinetic
Pharmacoeconomics
Personalized Therapy Biosimulation Platform Segment by Application
Pharmaceutical and Biotech Companies
Research Institutions
Hospital
Others
Personalized Therapy Biosimulation Platform Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Personalized Therapy Biosimulation Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Personalized Therapy Biosimulation Platform key companies, revenue, market share, and recent developments.
3. To split the Personalized Therapy Biosimulation Platform breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Personalized Therapy Biosimulation Platform market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Personalized Therapy Biosimulation Platform significant trends, drivers, influence factors in global and regions.
6. To analyze Personalized Therapy Biosimulation Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Therapy Biosimulation Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Personalized Therapy Biosimulation Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Therapy Biosimulation Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Personalized Therapy Biosimulation Platform industry.
Chapter 3: Detailed analysis of Personalized Therapy Biosimulation Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Personalized Therapy Biosimulation Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Personalized Therapy Biosimulation Platform in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Pharmacokinetic
- Pharmacoeconomics
Applications
- Pharmaceutical and Biotech Companies
- Research Institutions
- Hospital
- Others
Companies covered
- Schrodinger
- In Silico Biosciences
- Genedata
- Physiomics
- Insilico Biotechology
- Chemical Computing Group ULC(CCG)
- Evidera
- AnyLogic
- Shanghai Lide
- Cellworks Group
- Certara
- Simulation Plus
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Personalized Therapy Biosimulation Platform Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Personalized Therapy Biosimulation Platform Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Personalized Therapy Biosimulation Platform Market Dynamics
- 2.1 Personalized Therapy Biosimulation Platform Industry Trends
- 2.2 Personalized Therapy Biosimulation Platform Industry Drivers
- 2.3 Personalized Therapy Biosimulation Platform Industry Opportunities and Challenges
- 2.4 Personalized Therapy Biosimulation Platform Industry Restraints
3 Personalized Therapy Biosimulation Platform Market by Company
- 3.1 Global Personalized Therapy Biosimulation Platform Company Revenue Ranking in 2025
- 3.2 Global Personalized Therapy Biosimulation Platform Revenue by Company (2021-2026)
- 3.3 Global Personalized Therapy Biosimulation Platform Company Ranking (2024-2026)
- 3.4 Global Personalized Therapy Biosimulation Platform Company Manufacturing Base and Headquarters
- 3.5 Global Personalized Therapy Biosimulation Platform Company Product Type and Application
- 3.6 Global Personalized Therapy Biosimulation Platform Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Personalized Therapy Biosimulation Platform Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Personalized Therapy Biosimulation Platform Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Personalized Therapy Biosimulation Platform Market by Type
- 4.1 Personalized Therapy Biosimulation Platform Type Introduction
- 4.1.1 Pharmacokinetic
- 4.1.2 Pharmacoeconomics
- 4.2 Global Personalized Therapy Biosimulation Platform Sales Value by Type
- 4.2.1 Global Personalized Therapy Biosimulation Platform Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Personalized Therapy Biosimulation Platform Sales Value by Type (2021-2032)
- 4.2.3 Global Personalized Therapy Biosimulation Platform Sales Value Share by Type (2021-2032)
5 Personalized Therapy Biosimulation Platform Market by Application
- 5.1 Personalized Therapy Biosimulation Platform Application Introduction
- 5.1.1 Pharmaceutical and Biotech Companies
- 5.1.2 Research Institutions
- 5.1.3 Hospital
- 5.1.4 Others
- 5.2 Global Personalized Therapy Biosimulation Platform Sales Value by Application
- 5.2.1 Global Personalized Therapy Biosimulation Platform Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Personalized Therapy Biosimulation Platform Sales Value by Application (2021-2032)
- 5.2.3 Global Personalized Therapy Biosimulation Platform Sales Value Share by Application (2021-2032)
6 Personalized Therapy Biosimulation Platform Regional Value Analysis
- 6.1 Global Personalized Therapy Biosimulation Platform Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Personalized Therapy Biosimulation Platform Sales Value by Region (2021-2032)
- 6.2.1 Global Personalized Therapy Biosimulation Platform Sales Value by Region: 2021-2026
- 6.2.2 Global Personalized Therapy Biosimulation Platform Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Personalized Therapy Biosimulation Platform Sales Value (2021-2032)
- 6.3.2 North America Personalized Therapy Biosimulation Platform Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Personalized Therapy Biosimulation Platform Sales Value (2021-2032)
- 6.4.2 Europe Personalized Therapy Biosimulation Platform Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Personalized Therapy Biosimulation Platform Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Personalized Therapy Biosimulation Platform Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Personalized Therapy Biosimulation Platform Sales Value (2021-2032)
- 6.6.2 South America Personalized Therapy Biosimulation Platform Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Personalized Therapy Biosimulation Platform Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Personalized Therapy Biosimulation Platform Sales Value Share by Country, 2025 VS 2032
7 Personalized Therapy Biosimulation Platform Country-level Value Analysis
- 7.1 Global Personalized Therapy Biosimulation Platform Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Personalized Therapy Biosimulation Platform Sales Value by Country (2021-2032)
- 7.2.1 Global Personalized Therapy Biosimulation Platform Sales Value by Country (2021-2026)
- 7.2.2 Global Personalized Therapy Biosimulation Platform Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.7.2 France Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.14.2 China Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.17.2 India Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Personalized Therapy Biosimulation Platform Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Personalized Therapy Biosimulation Platform Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Personalized Therapy Biosimulation Platform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Schrodinger
- 8.1.1 Schrodinger Company Information
- 8.1.2 Schrodinger Business Overview
- 8.1.3 Schrodinger Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.1.4 Schrodinger Personalized Therapy Biosimulation Platform Product Portfolio
- 8.1.5 Schrodinger Recent Developments
- 8.2 In Silico Biosciences
- 8.2.1 In Silico Biosciences Company Information
- 8.2.2 In Silico Biosciences Business Overview
- 8.2.3 In Silico Biosciences Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.2.4 In Silico Biosciences Personalized Therapy Biosimulation Platform Product Portfolio
- 8.2.5 In Silico Biosciences Recent Developments
- 8.3 Genedata
- 8.3.1 Genedata Company Information
- 8.3.2 Genedata Business Overview
- 8.3.3 Genedata Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.3.4 Genedata Personalized Therapy Biosimulation Platform Product Portfolio
- 8.3.5 Genedata Recent Developments
- 8.4 Physiomics
- 8.4.1 Physiomics Company Information
- 8.4.2 Physiomics Business Overview
- 8.4.3 Physiomics Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.4.4 Physiomics Personalized Therapy Biosimulation Platform Product Portfolio
- 8.4.5 Physiomics Recent Developments
- 8.5 Insilico Biotechology
- 8.5.1 Insilico Biotechology Company Information
- 8.5.2 Insilico Biotechology Business Overview
- 8.5.3 Insilico Biotechology Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.5.4 Insilico Biotechology Personalized Therapy Biosimulation Platform Product Portfolio
- 8.5.5 Insilico Biotechology Recent Developments
- 8.6 Chemical Computing Group ULC(CCG)
- 8.6.1 Chemical Computing Group ULC(CCG) Company Information
- 8.6.2 Chemical Computing Group ULC(CCG) Business Overview
- 8.6.3 Chemical Computing Group ULC(CCG) Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.6.4 Chemical Computing Group ULC(CCG) Personalized Therapy Biosimulation Platform Product Portfolio
- 8.6.5 Chemical Computing Group ULC(CCG) Recent Developments
- 8.7 Evidera
- 8.7.1 Evidera Company Information
- 8.7.2 Evidera Business Overview
- 8.7.3 Evidera Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.7.4 Evidera Personalized Therapy Biosimulation Platform Product Portfolio
- 8.7.5 Evidera Recent Developments
- 8.8 AnyLogic
- 8.8.1 AnyLogic Company Information
- 8.8.2 AnyLogic Business Overview
- 8.8.3 AnyLogic Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.8.4 AnyLogic Personalized Therapy Biosimulation Platform Product Portfolio
- 8.8.5 AnyLogic Recent Developments
- 8.9 Shanghai Lide
- 8.9.1 Shanghai Lide Company Information
- 8.9.2 Shanghai Lide Business Overview
- 8.9.3 Shanghai Lide Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.9.4 Shanghai Lide Personalized Therapy Biosimulation Platform Product Portfolio
- 8.9.5 Shanghai Lide Recent Developments
- 8.10 Cellworks Group
- 8.10.1 Cellworks Group Company Information
- 8.10.2 Cellworks Group Business Overview
- 8.10.3 Cellworks Group Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.10.4 Cellworks Group Personalized Therapy Biosimulation Platform Product Portfolio
- 8.10.5 Cellworks Group Recent Developments
- 8.11 Certara
- 8.11.1 Certara Company Information
- 8.11.2 Certara Business Overview
- 8.11.3 Certara Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.11.4 Certara Personalized Therapy Biosimulation Platform Product Portfolio
- 8.11.5 Certara Recent Developments
- 8.12 Simulation Plus
- 8.12.1 Simulation Plus Company Information
- 8.12.2 Simulation Plus Business Overview
- 8.12.3 Simulation Plus Personalized Therapy Biosimulation Platform Revenue and Gross Margin (2021-2026)
- 8.12.4 Simulation Plus Personalized Therapy Biosimulation Platform Product Portfolio
- 8.12.5 Simulation Plus Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst